NCT00470678View on ClinicalTrials.gov

EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

PHASE3CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Choroidal NeovascularizationAge-Related Macular Degeneration
Interventions
DRUG

ranibizumab

Trial Locations (6)

Unknown

Novartis Investigative Site, Daegu

Novartis Investigative Site, Pusan

Novartis Investigative site, Seoul

Novartis Investigative Site, Kaohsiung City

Novartis Investigative Site, Linkou District

Novartis Investigative site, Taipei

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY